Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations.

[1]  R. Gabbay,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). , 2022, Diabetes care.

[2]  Sandra L. Weber,et al.  American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. , 2022, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[3]  M. Riddle,et al.  Standards of Medical Care in Diabetes—2020 Abridged for Primary Care Providers , 2019, Clinical Diabetes.

[4]  V. Mohan,et al.  Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians , 2019, Diabetes Therapy.

[5]  S. Hahn,et al.  Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis , 2018, Scientific Reports.

[6]  C. Mathieu,et al.  Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes , 2015, Diabetes Care.

[7]  Dacheng Liu,et al.  Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin , 2015, Diabetes Care.

[8]  J. Rosenstock,et al.  Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin , 2014, Diabetes Care.

[9]  É. Hardy,et al.  Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study , 2014, Diabetes Care.

[10]  K. Khunti,et al.  Clinical Inertia in People With Type 2 Diabetes , 2013, Diabetes Care.

[11]  Silvio E. Inzucchi,et al.  Personalized Management of Hyperglycemia in Type 2 Diabetes , 2013, Diabetes Care.

[12]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.

[13]  S. Del Prato,et al.  Multidrug Treatment of Type 2 Diabetes , 2011, Diabetes Care.

[14]  Ralph A. DeFronzo,et al.  From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus , 2009, Diabetes.

[15]  M. Ihnat,et al.  Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications? , 2009, The Journal of clinical endocrinology and metabolism.

[16]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[17]  A. Cheng.  Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction. , 2013, Canadian journal of diabetes.